Physician profile
Douglas Robert Sinclair
NPI 1356404107
$10,315.30
in general payments reported to CMS, 2019-2025
64 companies · $1,905 in 2025
The $1,905 reported for 2025 was more than what a typical Neuromuscular Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,838 · 2020: $415 · 2021: $259 · 2022: $1,740 · 2023: $1,330 · 2024: $1,829 · 2025: $1,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,063.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,191.47 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $693.04 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $579.50 | 2019-2025 | Nuplazid |
| Lundbeck LLC | $467.25 | 2019-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $415.30 | 2019-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $403.41 | 2019-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $400.95 | 2019-2025 | Fintepla, Rystiggo, Briviact |
| Teva Pharmaceuticals USA, INC. | $363.02 | 2019-2024 | Austedo Xr, Austedo |
| Genzyme Corporation | $357.93 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $352.46 | 2019-2025 | Ultomiris, Soliris |
| Eisai INC. | $351.71 | 2019-2025 | |
| Genentech USA, INC. | $289.34 | 2019-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Supernus Pharmaceuticals, INC. | $284.47 | 2019-2020 | |
| Amgen INC. | $281.44 | 2019-2025 | Uplizna |
| Acorda Therapeutics, INC | $271.63 | 2019-2023 | Inbrija |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Sinclair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.